“IS IT SAFE AND COST SAVING TO DEFER THE CD4+ CELL COUNT MONITORING IN STABLE PATIENTS ON ART WITH MORE THAN 350 OR 500 CELLS/µL?” (2019) Mediterranean Journal of Hematology and Infectious Diseases, 11(1), p. e2019063. doi:10.4084/mjhid.2019.063.